AMNEAL PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.87 USD | -0.51% |
|
+8.30% | -3.29% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 646.3 | 674.7 | 715.5 | 301.4 | 1,861 | 1,811 | - | - |
| Enterprise Value (EV) 1 | 3,187 | 3,210 | 3,169 | 2,888 | 4,182 | 4,103 | 3,886 | 3,664 |
| P/E ratio | -1.76 x | 7.49 x | 68.4 x | -2.31 x | -12.6 x | 117 x | 65.2 x | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.4 x | 0.34 x | 0.34 x | 0.14 x | 0.78 x | 0.7 x | 0.66 x | 0.64 x |
| EV / Revenue | 1.96 x | 1.61 x | 1.51 x | 1.31 x | 1.75 x | 1.58 x | 1.42 x | 1.3 x |
| EV / EBITDA | 8.96 x | 7.04 x | 5.89 x | 5.62 x | 7.49 x | 6.86 x | 6.28 x | 5.76 x |
| EV / FCF | -70.1 x | 9.95 x | 16.3 x | 155 x | 13.8 x | 13.8 x | 12.7 x | 9.96 x |
| FCF Yield | -1.43% | 10% | 6.12% | 0.65% | 7.23% | 7.25% | 7.85% | 10% |
| Price to Book | 6.22 x | 4.52 x | 4.01 x | 2.02 x | 54.1 x | 3.83 x | 2.6 x | 1.94 x |
| Nbr of stocks (in thousands) | 134,096 | 147,628 | 149,371 | 151,476 | 306,544 | 308,554 | - | - |
| Reference price 2 | 4.820 | 4.570 | 4.790 | 1.990 | 6.070 | 5.870 | 5.870 | 5.870 |
| Announcement Date | 2/26/20 | 2/26/21 | 3/1/22 | 3/2/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,626 | 1,993 | 2,094 | 2,212 | 2,394 | 2,603 | 2,728 | 2,818 |
| EBITDA 1 | 355.5 | 456.2 | 538.1 | 514.1 | 558.2 | 598.1 | 618.5 | 636.5 |
| EBIT 1 | 292.2 | 325.6 | 387.9 | 343.3 | 379.1 | 521.1 | 533.6 | 543.6 |
| Operating Margin | 17.97% | 16.34% | 18.53% | 15.52% | 15.84% | 20.02% | 19.56% | 19.29% |
| Earnings before Tax (EBT) 1 | -220.2 | -35.78 | - | - | -40.72 | 46.74 | 89.25 | - |
| Net income 1 | -603.6 | 68.58 | 20.17 | - | -83.99 | 14.44 | 22.71 | 18.4 |
| Net margin | -37.11% | 3.44% | 0.96% | - | -3.51% | 0.55% | 0.83% | 0.65% |
| EPS 2 | -2.740 | 0.6100 | 0.0700 | -0.8600 | -0.4800 | 0.0500 | 0.0900 | - |
| Free Cash Flow 1 | -45.48 | 322.6 | 194.1 | 18.69 | 302.4 | 297.3 | 305.2 | 368 |
| FCF margin | -2.8% | 16.19% | 9.27% | 0.84% | 12.63% | 11.42% | 11.19% | 13.06% |
| FCF Conversion (EBITDA) | - | 70.71% | 36.07% | 3.64% | 54.17% | 49.71% | 49.34% | 57.82% |
| FCF Conversion (Net income) | - | 470.35% | 962.28% | - | - | 2,058.66% | 1,343.62% | 2,000% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/26/20 | 2/26/21 | 3/1/22 | 3/2/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 528.6 | 536.9 | 497.6 | 559.4 | 545.6 | 609.8 | 557.5 | 599 | 620 | 617 | 618.1 | 650.4 | 666.7 | 668.1 | 649.7 |
| EBITDA 1 | 134.9 | 126.4 | 99.86 | 134.6 | 125.6 | 154 | 116.2 | 146.1 | 153.8 | 142.1 | 129.9 | 143.9 | 154.6 | 163.6 | 149.5 |
| EBIT 1 | 116.4 | 77.96 | 81.31 | 119.4 | 106.8 | 105.3 | 128.7 | 124.3 | 131.9 | 92.98 | 108.6 | 131.1 | 140.2 | 141.1 | 106.5 |
| Operating Margin | 22.02% | 14.52% | 16.34% | 21.35% | 19.58% | 17.27% | 23.09% | 20.76% | 21.28% | 15.07% | 17.58% | 20.16% | 21.03% | 21.12% | 16.39% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | - | - | - | 22.96 | -83.46 | -3.878 | 3.316 | 18.62 | 28.69 | 18.01 |
| Net income 1 | -4.237 | -20.46 | -2.156 | -120.8 | - | - | - | - | 9.682 | -98.65 | -1.21 | 1.034 | 5.809 | 8.951 | 5.655 |
| Net margin | -0.8% | -3.81% | -0.43% | -21.6% | - | - | - | - | 1.56% | -15.99% | -0.2% | 0.16% | 0.87% | 1.34% | 0.87% |
| EPS 2 | -0.0300 | -0.0400 | -0.0100 | -0.8000 | -0.0200 | -0.0300 | -0.0500 | 0.0800 | 0.0600 | -0.4000 | - | - | 0.0200 | 0.0300 | 0.0200 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 3/1/22 | 5/4/22 | 8/5/22 | 11/4/22 | 3/2/23 | 5/5/23 | 8/4/23 | 11/7/23 | 3/1/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 2,541 | 2,536 | 2,454 | 2,587 | 2,321 | 2,292 | 2,074 | 1,852 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 7.147 x | 5.559 x | 4.561 x | 5.031 x | 4.158 x | 3.832 x | 3.354 x | 2.91 x |
| Free Cash Flow 1 | -45.5 | 323 | 194 | 18.7 | 302 | 297 | 305 | 368 |
| ROE (net income / shareholders' equity) | 28.1% | 71.4% | 75.5% | 75.4% | 194% | 34.3% | 26.4% | 21.3% |
| ROA (Net income/ Total Assets) | 2.58% | 4.98% | 6.5% | 5.37% | 5.43% | 4.57% | 4.67% | 4.77% |
| Assets 1 | -23,360 | 1,377 | 310.5 | - | -1,546 | 315.9 | 486.3 | 386 |
| Book Value Per Share 2 | 0.7800 | 1.010 | 1.200 | 0.9800 | 0.1100 | 1.530 | 2.260 | 3.020 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 47.2 | 56.4 | 47.7 | 46.4 | 43.2 | 59.1 | 61.9 | 58.2 |
| Capex / Sales | 2.9% | 2.83% | 2.28% | 2.1% | 1.81% | 2.27% | 2.27% | 2.06% |
| Announcement Date | 2/26/20 | 2/26/21 | 3/1/22 | 3/2/23 | 3/1/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
5.87
USD
Average target price
7.312
USD
Spread / Average Target
+24.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.29% | 1.81B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- AMRX Stock
- Financials Amneal Pharmaceuticals, Inc.
